Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting

Annals of Thoracic Surgery

Volumn 76, Issue 1, 2003, Pages 124-128

  Kincaid, Edward H ^a   Monroe, Michelle L ^a   Saliba, David L ^a   Kon, Neal D ^a   Byerly, Wesley G ^a   Reichert, Marc G ^a   Pennington, D Glenn ^b   Mcdonald, Jerome M ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Wake Forest Univ School of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING TENDENCY; BLOOD TRANSFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEMOGRAPHY; ERYTHROCYTE CONCENTRATE; FEMALE; HEMATOLOGY; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; HEMOGLOBINS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037662201     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)00190-5     Document Type: Article

References (19)

1. Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex and severity of infarction. JAMA 1972;225:724-9.
2. Chalmers TC, Matta RJ, Smith H Jr, Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091-6.
3. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981;1:1225-8.
4. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-8.
5. Cohen M, Demers C, Gurfinkel EP, et al, for the Efficacy, and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
6. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
7. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
8. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina, and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). March 2002. Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.
9. Clark SC, Vitale N, Zacharias J, Forty J. Effect of low molecular weight heparin (Fragmin) on bleeding after cardiac surgery. Ann Thorac Surg 2000;69:762-5.
10. Jones HU, Muhlestein JB, Jones KW, et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome. Circulation 2002;106:I19-22.
11. Skubas NJ, Despotis GJ, Vlasnic JJ, Moon MR. Preoperative use of enoxaparin and tirofiban: possible association with increased bleeding postbypass. Anesthesiology 1999;91:869-72.
12. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72:308-18.
13. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-6.
14. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
15. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001;13:272-8.
16. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. FRagmin In unstable Coronary artery disease study (FRIC). Circulation 1997;96:61-8.
17. FRAXIS Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction. FRAX.I.S. (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20:553-62.
18. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-7.
19. Gammie JS, Zenati M, Kormos RL, et al. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg 1998;65:465-9.